WALD WALDENCAST ACQUISITION CORP

Obagi Medical Announces the Launch of ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate

Obagi Medical Announces the Launch of ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate

These New Products are the Latest Innovation to Obagi’s ELASTIDERM® Collection



 

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation and pioneer in medical-grade skincare and a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), proudly announces the launch of two groundbreaking skincare products: ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate. Both products deliver transformative results, leveraging cutting-edge technology and advanced formulations to enhance skin appearance and texture.

The ELASTIDERM® Lift Up & Sculpt Facial Moisturizer is clinically proven to visibly lift and sculpt facial contours. This advanced moisturizer actively supports skin's elasticity through Obagi's patented Bi-Mineral Contour Complex™, which combines Zinc, Copper, and Malonate to help support skin elasticity and target the signs of skin aging. It incorporates Polyglutamic Acid (PGA), a peptide known for its superior hydrating properties to provide intense hydration and help re-plump fine lines and wrinkles. The result is a visibly lifted, sculpted appearance with improved fullness, smoothness, and skin texture in just 6 weeks.*

The ELASTIDERM® Advanced Filler Concentrate offers a targeted solution for fine lines and wrinkles formulated with Acetyl Hexapeptide-1, an ingredient renowned for its effective re-plumping and wrinkle-smoothing benefits. The concentrate, applied topically with a precision applicator, delivers immediate filling effects for existing fine lines, while helping diminish wrinkles over time. This non-injectable solution is designed to provide a visibly lifted and youthful appearance by targeting emerging fine lines and wrinkles.*

Eman Kadhim, Head of Scientific Communications & Upstream Innovation at Waldencast, commented, “The release of the latest ELASTIDERM® products marks a notable advancement in dermatological research. These products incorporate our proprietary Bi-Mineral Contour Complex™ and Acetyl Hexapeptide-1, which were rigorously tested and proven effective in enhancing skin elasticity and hydration. These formulations enhance overall skin texture, underscoring our commitment to integrating cutting-edge scientific research and ingredients into practical, effective skincare solutions."

Justin Giouzepis, Chief Marketing Officer of Obagi Cosmeceuticals, added, “At Obagi, we are dedicated to supporting our valued physician and professional partners by providing products that enhance their anti-aging treatments. Our formulations are designed to complement in-office procedures, ensuring a comprehensive approach to skincare. Additionally, for those who seek transformative solutions for fine lines, wrinkles, and aging skin outside of clinical settings, the ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate products offer effective, high-quality alternatives to help them achieve their skincare goals."

ELASTIDERM® Lift Up & Sculpt Facial Moisturizer, priced at $135, and the ELASTIDERM® Advanced Filler Concentrate, priced at $115, are now available through partnering professional channels. They will be available for customers to purchase on  on September 23rd.

*Results based on 2024 clinical tests. Data on file at Obagi Cosmeceuticals LLC.

About Obagi Medical

Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, refined with a legacy of 35 years’ experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. Backed by science and trusted by professionals, Obagi empowers individuals to achieve healthy, beautiful skin. More information about Obagi is available on the brand’s website, .

About Waldencast

Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Cosmeceuticals and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset-light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: .

Media Contact:

Photos accompanying this announcement are available at



EN
09/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WALDENCAST ACQUISITION CORP

 PRESS RELEASE

Waldencast Reports Q3 2024 Financial Results

Waldencast Reports Q3 2024 Financial Results $70.2 million of Net Revenue Q3 2024+34.6% Comparable Net Revenue GrowthBoth brands accelerating from Q2 2024+45.5% Obagi Medical and +23.5% Milk Makeup vs Q3 2023Adjusted EBITDA of $11.4 million, up +134.0% vs Q3 2023 LONDON, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended September 30, 2024 (“Q3 2024”) and nine months ended September 30, 2024 ("Nine Months 2024") on Form 6-K to the U....

 PRESS RELEASE

Waldencast plc Announces Third Quarter Fiscal 2024 Results Conference ...

Waldencast plc Announces Third Quarter Fiscal 2024 Results Conference Call and Webcast LONDON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its Third Quarter Fiscal 2024 conference call and webcast. As previously announced, the Company will issue its Third Quarter Fiscal 2024 results on November 20, 2024 after the close of the U.S. market. Management will host a conference call to discuss its Third Quarter Fiscal 2024 results on November 21, 2024 at 8:30am ET.   Investors and an...

 PRESS RELEASE

Waldencast plc Announces Board Appointments and Annual General Meeting

Waldencast plc Announces Board Appointments and Annual General Meeting NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, announced today that Hind Sebti, Kelly Brookie and Roberto Thompson have been appointed to its board of Directors (the “Board”), effective September 26, 2024. These executives bring extensive professional experience further enhancing the breadth of talent and expertise possessed by the Board. Ms. Brookie will replace Sarah Brown who has informed the Board of her i...

 PRESS RELEASE

Obagi Medical Announces the Launch of ELASTIDERM® Lift Up & Sculpt Fac...

Obagi Medical Announces the Launch of ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate These New Products are the Latest Innovation to Obagi’s ELASTIDERM® Collection   NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation and pioneer in medical-grade skincare and a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), proudly announces the launch of two groundbreaking skincare products: ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate. ...

 PRESS RELEASE

Waldencast Reports Q2 2024 Financial Results

Waldencast Reports Q2 2024 Financial Results $63.3 million of Net Revenue Q2 2024 +25.7% net revenue Comparable Growth: +30.9% Obagi Medical and +20.0% Milk Makeup vs Q2 2023 Adjusted EBITDA of $6.3 million, up +64.5% vs Q2 2023 NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended June 30, 2024 (“Q2 2024”) and six months ended June 30, 2024 ("H1 2024") on Form 6-K to the U.S. Securities and Exchange Commission, which ar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch